专家声音：Cell子刊两文聚焦菌群与癌症治疗 | 热情肠日报
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q8.itc.cn/q_70/images01/20240302/8730dbd7b41f4fd99e7e631f751f4365.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q9.itc.cn/q_70/images01/20240422/a51fff39bc24436d8f37676ed3eeadb2.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该篇日报由R·AI辅助创作生成，人工审核校对。</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Cell子刊：微生物组与癌症免疫治疗（专家观点）</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Cell Reports Medicine——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① <span style="color: black;">文案</span>分别采访了陈豪燕、Laurence Zitvogel、彭智、Florencia McAllister等肿瘤微生物<span style="color: black;">科研</span>专家，探讨了微生物组<span style="color: black;">怎样</span>影响癌症<span style="color: black;">病人</span>、治疗和临床<span style="color: black;">科研</span>；② 临床微生物组分析面临的挑战<span style="color: black;">包含</span><span style="color: black;">病人</span>临床<span style="color: black;">繁杂</span>性对微生物组的影响，<span style="color: black;">膳食</span>和环境暴露对微生物组效应的干扰，癌症治疗多样性<span style="color: black;">引起</span>难以<span style="color: black;">知道</span>治疗反应，缺乏高质量纵向微生物组数据；③ 肠道微生物组的失调影响全身炎症、免疫、代谢和神经内分泌系统，可能降低免疫治疗的效果，而<span style="color: black;">经过</span>口服<span style="color: black;">繁杂</span>生态系统或活性生物制剂或可改善；④ 胃癌中，微生物组可能影响治疗反应和<span style="color: black;">病人</span><span style="color: black;">存活</span>，特定微生物类群可能<span style="color: black;">做为</span>免疫治疗预后标志物，微生物组<span style="color: black;">干涉</span>策略<span style="color: black;">表示</span>出<span style="color: black;">加强</span>治疗效果的<span style="color: black;">潜能</span>；⑤ <span style="color: black;">将来</span>，微生物组对临床护理的影响将<span style="color: black;">经过</span>整合肿瘤基因组学、转录组学、代谢组学和微生物信息，结合人工智能<span style="color: black;">指点</span>个体化治疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Microbiome and cancer immunotherapies</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-16 , doi: 10.1016/j.xcrm.2024.101514</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Cell子刊：肠道菌群与免疫治疗——前景与挑战（专家访谈）</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Cell Reports Medicine——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 这篇访谈<span style="color: black;">文案</span>中，Jennifer Wargo、Nadim Ajami和Carrie Daniel-MacDougall探讨了微生物组对癌症治疗的影响以及临床实践中的应用和挑战；② 微生物组在临床癌症治疗上<span style="color: black;">拥有</span>多种潜在应用，例如<span style="color: black;">经过</span>粪菌移植、合成菌群、靶向肿瘤<span style="color: black;">关联</span>微生物和<span style="color: black;">膳食</span>营养<span style="color: black;">干涉</span>等<span style="color: black;">办法</span>改善疗效，以及<span style="color: black;">评定</span>抗生素对治疗效果的影响；③ <span style="color: black;">创立</span>微生物组分析、样本处理和数据报告的<span style="color: black;">办法</span>学标准，<span style="color: black;">思虑</span>个体差异，<span style="color: black;">公司</span>内资源最大化以促进跨学科合作，有助于克服临床转化和<span style="color: black;">干涉</span>层面的挑战；④ <span style="color: black;">经过</span><span style="color: black;">膳食</span><span style="color: black;">干涉</span>调控肠道菌群以优化<span style="color: black;">病人</span>免疫状态和治疗反应<span style="color: black;">拥有</span>前景，但在<span style="color: black;">科研</span>和实施中<span style="color: black;">亦</span>存在<span style="color: black;">繁杂</span>性和可<span style="color: black;">连续</span>性等挑战。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Jennifer A. Wargo, Nadim J. Ajami, and Carrie R. Daniel-MacDougall</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-16 , doi: 10.1016/j.xcrm.2024.101509</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">李雪团队：空气污染与结直肠癌<span style="color: black;">危害</span>的表观遗传学<span style="color: black;">相关</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">EBioMedicine——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 空气污染会改变宿主免疫系统、改变表观遗传学标记，但其<span style="color: black;">怎样</span><span style="color: black;">经过</span>影响表观遗传学介导结直肠癌（CRC）进程尚未解析，浙江大学医学院李雪与团队基于UK BioBank临床数据和孟德尔随机化对其进行了<span style="color: black;">科研</span>；② 从UK Biobank纳入了428632名受试者及其临床数据和环境报告，基于PM<span style="color: black;">十、</span>PM2.5、NOx、NO2数据引入空气污染暴露评分（APES），<span style="color: black;">发掘</span>高APES与<span style="color: black;">增多</span>的CRC<span style="color: black;">危害</span>和较差的<span style="color: black;">存活</span>率<span style="color: black;">关联</span>，尤其是在体力活动不足和吸烟者中表现<span style="color: black;">显著</span>；③ 对之前PM2.5与CRC<span style="color: black;">危害</span><span style="color: black;">科研</span>进行荟萃分析，证实了PM2.5暴露<span style="color: black;">增多</span>与CRC<span style="color: black;">危害</span><span style="color: black;">上升</span>的<span style="color: black;">相关</span>；④ 结合孟德尔随机化和GWAS分析<span style="color: black;">发掘</span>PM2.5<span style="color: black;">关联</span>的TMBIM1/PNKD基因、CXCR5基因、NO2<span style="color: black;">关联</span>的TMEM110基因甲基化位点与CRC<span style="color: black;">危害</span><span style="color: black;">增多</span><span style="color: black;">关联</span>；⑤ <span style="color: black;">经过</span>基因-环境互作分析验证了与PM2.5和NO2暴露<span style="color: black;">关联</span>的甲基化位点与CRC<span style="color: black;">危害</span>和死亡率<span style="color: black;">增多</span>的<span style="color: black;">相关</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Impact of ambient air pollution on colorectal cancer risk and survival: insights from a prospective cohort and epigenetic Mendelian randomization study</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-16 , doi: 10.1016/j.ebiom.2024.105126</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">国内团队：XELOX+贝伐单抗+PD1-T联用，或可<span style="color: black;">做为</span>转移性大肠癌一线治疗<span style="color: black;">方法</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Signal Transduction and Targeted Therapy——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 郑州大学的张毅、苏州大学的蒋敬庭、天津医科大学的任秀宝和中山大学的夏建川团队合作<span style="color: black;">发布</span>了一项3期临床结果，在未经治疗的转移性结直肠癌（mCRC）<span style="color: black;">病人</span>中，PD-1阻断激活的DC-CIK（PD1-T）细胞联合XELOX和贝伐珠单抗<span style="color: black;">做为</span>一线治疗，<span style="color: black;">表示</span>出<span style="color: black;">明显</span>的PFS和OS临床改善，并且耐受性良好；② 招募202名参与者，随机接受XELOX+贝伐单抗（对照组）或相同<span style="color: black;">方法</span>加自体PD1-T细胞免疫治疗，每21天一次，最多6个疗程，随后进行卡培他滨和贝伐单抗的维持治疗；③ 中位随访期19.5个月，免疫疗法组的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期（PFS）为14.8个月，<span style="color: black;">明显</span>优于对照组的9.9个月；④ 免疫疗法组的中位总<span style="color: black;">存活</span>期（OS）尚未达到，而对照组为25.6个月；⑤ 两组<span style="color: black;">病人</span>中3级或更高级别的不良事件（AEs）<span style="color: black;">出现</span>率相近，免疫疗法组为20.0%，对照组为23.5%，未报告与毒性<span style="color: black;">关联</span>的死亡。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-03 , doi: 10.1038/s41392-024-01788-2</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">中山六院：新辅助化疗——局部晚期结肠癌的可行治疗<span style="color: black;">选取</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Journal of Clinical Oncology——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 中山大学<span style="color: black;">附庸</span>第六医院邓艳红与团队<span style="color: black;">发布</span>临床<span style="color: black;">科研</span>OPTICAL，这是一项随机对照3期<span style="color: black;">实验</span>，旨在<span style="color: black;">评定</span>新辅助化疗在局部晚期结肠癌中的<span style="color: black;">功效</span>；② 共纳入752例临床局部晚期结肠癌<span style="color: black;">病人</span>，<span style="color: black;">根据</span>1:1随机分为6周期mFOLFOX6或4周期CAPOX，随后手术与辅助化疗（NAC组），或即刻手术与医师<span style="color: black;">选取</span>辅助化疗（直接手术组）；③ .平均48个月的随访中，NAC组的3年<span style="color: black;">没</span>病<span style="color: black;">存活</span>期率为82.1%，而直接手术组为77.5%；④ 相比直接手术组，NAC组实现了7%的病理完全缓解率，降低了高级别肿瘤分期和淋巴结转移的比例；⑤ NAC组的整体<span style="color: black;">存活</span>率可能有所<span style="color: black;">加强</span>，<span style="color: black;">表示</span>出新辅助化疗是一种可行的治疗<span style="color: black;">选取</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-02 , doi: 10.1200/JCO.23.01889</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">Nature子刊：SMARCB1是结直肠癌分化的负调控因子</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Nature Communications——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 本<span style="color: black;">科研</span><span style="color: black;">经过</span>构建双内源报告系统，成功鉴定了影响结直肠癌（CRC）中干细胞样活性和分化<span style="color: black;">阻碍</span>的<span style="color: black;">重要</span>调控因子，为<span style="color: black;">研发</span>新的治疗策略<span style="color: black;">供给</span>了可能；② <span style="color: black;">经过</span>基因编辑技术在人类CRC细胞系的SOX9和KRT20位点引入荧光报告基因，用以监测干细胞样活性和<span style="color: black;">反常</span>的分化；③ <span style="color: black;">经过</span>针对78个表观遗传调控因子的CRISPR筛选，识别出影响CRC干细胞样活性和分化的因子；④ 经过Perturb-seq验证的结果<span style="color: black;">表示</span>，BAF复合体的成员SMARCB1是多种结肠肿瘤模型中分化的负调控因子，且对人类CRC模型在<span style="color: black;">身体</span>生长是必需的。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-03-12 , doi: 10.1038/s41467-024-46285-w</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">9种有效改善结肠镜<span style="color: black;">检测</span>质量的<span style="color: black;">干涉</span><span style="color: black;">办法</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Gastroenterology——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 本<span style="color: black;">科研</span><span style="color: black;">经过</span>网络荟萃分析，纳入124项<span style="color: black;">实验</span>，<span style="color: black;">评定</span>了37种<span style="color: black;">干涉</span><span style="color: black;">办法</span>对<span style="color: black;">加强</span>筛查<span style="color: black;">关联</span>结肠镜<span style="color: black;">检测</span>质量的相对效果，<span style="color: black;">发掘</span>九种<span style="color: black;">干涉</span><span style="color: black;">办法</span>能<span style="color: black;">明显</span><span style="color: black;">加强</span>腺瘤检出率（ADR）；② 这些<span style="color: black;">干涉</span><span style="color: black;">办法</span><span style="color: black;">包含</span>9分钟撤退时间、双重观察、水交换、iScan™、联合色彩<span style="color: black;">影像</span>、计算机辅助检测、Endocuff™、Endocuff Vision™和口服亚甲蓝；③ 在<span style="color: black;">加强</span>ADR方面，双重观察和水交换在术中技术中排名最高，iScan™、联合色彩<span style="color: black;">影像</span>和计算机辅助检测在内窥镜技术中排名最高，WingCap和Endocuff™在远端附件设备中排名最高，口服亚甲蓝在添加剂中排名最高；④ <span style="color: black;">无</span><span style="color: black;">干涉</span><span style="color: black;">办法</span>能改善高级腺瘤的检测，狭窄带<span style="color: black;">影像</span>是<span style="color: black;">独一</span>一种能<span style="color: black;">加强</span>锯齿状病变检出率的<span style="color: black;">干涉</span><span style="color: black;">办法</span>；⑤ 结果<span style="color: black;">表示</span>，<span style="color: black;">有些</span><span style="color: black;">干涉</span><span style="color: black;">办法</span>在改善腺瘤检测和结肠镜<span style="color: black;">检测</span>质量方面是有效的，其中许<span style="color: black;">大都是</span>免费的，这些结果为内镜医师、单位管理者和内镜学会<span style="color: black;">供给</span>了关于<span style="color: black;">各样</span><span style="color: black;">干涉</span><span style="color: black;">办法</span>相对效果的信息。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Relative Efficacies of Interventions to Improve the Quality of Screening-related Colonoscopy: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-03-19 , doi: 10.1053/j.gastro.2024.03.018</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">北京协和医院：问卷+FIT策略进行结肠镜筛查更经济<span style="color: black;">有效</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PLoS Medicine——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 北京协和医学院的李霓和赫捷团队合作<span style="color: black;">发布</span><span style="color: black;">文案</span>，<span style="color: black;">发掘</span>基于问卷调查收集<span style="color: black;">危害</span><span style="color: black;">原因</span>数据（RF策略）和粪便免疫化学<span style="color: black;">实验</span>结果（RF-FIT策略）相结合进行结直肠癌筛查，参与度、经济性和检出率方面更好；② CanSPUC和WHOLE队列分别采用RF和RF-FIT策略，RF-FIT组和RF组有71,967人（7.65%）和281,985人（18.47%）被识别为高<span style="color: black;">危害</span>，被邀请接受结肠镜<span style="color: black;">检测</span>；③ RF-FIT和RF组的结肠镜参与率为26.50%和19.54%，RF-FIT检出102例（0.53%）结直肠癌和2,074例（10.88%）高级别腺瘤，而RF检出90例（0.16%）结直肠癌和3,593例（6.52%）高级别腺瘤；④ RF-FIT策略的<span style="color: black;">初期</span>检出率<span style="color: black;">明显</span>高于RF策略（67.05% vs47.95%）；⑤ RF-FIT策略每检出一例结直肠癌的成本为24,849美元，而RF策略为55,846美元。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort study</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-02-22 , doi: 10.1371/journal.pmed.1004340</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">2024年欧洲癌症死亡率预测及结肠癌趋势</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Annals of Oncology——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 该<span style="color: black;">科研</span>预测，2024年欧盟和英国的癌症死亡率及结直肠癌死亡率呈整体降低趋势，但<span style="color: black;">青年</span>人的结直肠癌死亡率呈<span style="color: black;">增多</span>趋势；② 预测<span style="color: black;">表示</span>，2024年欧盟的癌症死亡人数为1,270,800例，自2018年，男性癌症死亡率下降6.5%至123.2/10万人，女性下降4.3%至79.0/10万人；③ 自1988年，欧盟及英国分别避免了约620万例及130万例癌症死亡；④ 欧盟及英国男性的各年龄段的结直肠癌死亡率均下降，自2018年，男性及女性分别降低4.8%及9.5%，但50岁以下的结直肠癌死亡率呈<span style="color: black;">有害</span>趋势；⑤ 胰腺癌和女性肺癌的死亡率呈<span style="color: black;">有害</span>趋势；⑥ 该结果对癌症防控和公共卫生政策<span style="color: black;">拥有</span><span style="color: black;">指点</span><span style="color: black;">道理</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">European cancer mortality predictions for the year 2024 with focus on colorectal cancer</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-01-17 , doi: 10.1016/j.annonc.2023.12.003</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;"><span style="color: black;">药品</span>预防和治疗癌症<span style="color: black;">病人</span>阿片类<span style="color: black;">药品</span><span style="color: black;">导致</span>的便秘（荟萃分析）</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Cancer Treatment Reviews——</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 本<span style="color: black;">科研</span>比较了预防或治疗癌症<span style="color: black;">病人</span><span style="color: black;">因为</span>阿片类<span style="color: black;">药品</span><span style="color: black;">导致</span>的便秘（OIC）的<span style="color: black;">药品</span>策略，<span style="color: black;">发掘</span>氧化镁和纳地美定对预防OIC有效，而纳洛酮+羟考酮和纳地美定+甲基纳曲酮的组合对治疗OIC有效，且副<span style="color: black;">功效</span>可接受；② 在预防OIC方面，氧化镁与<span style="color: black;">没</span>泻药相比、纳地美定与氧化镁相比，效果更<span style="color: black;">明显</span>，<span style="color: black;">然则</span>羟考酮+纳洛酮与羟考酮或芬太尼相比未<span style="color: black;">表示</span>出<span style="color: black;">明显</span>差异；③ 在治疗OIC方面，聚乙二醇与番泻叶甙相比、羟考酮+纳洛酮与羟考酮+泻药相比、纳地美定+甲基纳曲酮与安慰剂相比，均<span style="color: black;">表示</span>出<span style="color: black;">明显</span>改善效果，羟考酮+纳洛酮<span style="color: black;">更易</span><span style="color: black;">导致</span>恶心；④ 在不良事件方面，<span style="color: black;">运用</span>甲基纳曲酮治疗的<span style="color: black;">病人</span>腹痛较多，<span style="color: black;">运用</span>纳地美定治疗的<span style="color: black;">病人</span>腹泻较多，<span style="color: black;">区别</span>剂量甲基纳曲酮的疗效和不良事件<span style="color: black;">出现</span>率<span style="color: black;">没</span><span style="color: black;">明显</span>差异；⑤ 尽管这些<span style="color: black;">药品</span><span style="color: black;">表示</span>出对OIC的预防和治疗有效，但与标准泻药（渗透性或刺激性泻药）尚缺乏比较，<span style="color: black;">必须</span><span style="color: black;">更加多</span><span style="color: black;">科研</span>以应用于临床。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-03-01 , doi: 10.1016/j.ctrv.2024.102704</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">四川厌氧生物与皇氏乳业达成战略合作</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 4月18日，四川厌氧生物科技有限责任<span style="color: black;">机构</span>与皇氏乳业集团<span style="color: black;">签定</span>战略合作协议；② 双方将<span style="color: black;">一起</span><span style="color: black;">开发</span>适合中国市场的酸奶发酵剂和益生功能菌株，<span style="color: black;">提高</span>皇氏酸奶<span style="color: black;">制品</span>的<span style="color: black;">口味</span>和营养价值；③ 合作将推动我国乳业科技进步和产业升级，双方将在技术<span style="color: black;">开发</span>、市场拓展等方面深化合作；④ 皇氏乳业集团是一家全产业链发展的上市<span style="color: black;">机构</span>，致力于水牛奶产业；⑤ 四川厌氧生物专注于微生态<span style="color: black;">药品</span>开发，<span style="color: black;">持有</span>完整的“从菌到药”核心技术和资源库。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">四川厌氧生物与皇氏乳业集团达成战略合作！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-19 , 厌氧生物</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">胃球囊<span style="color: black;">瘦身</span><span style="color: black;">制品</span><span style="color: black;">机构</span>「Allurion」<span style="color: black;">得到</span>4800万美元融资</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 4月17日，Allurion<span style="color: black;">机构</span>宣布完<span style="color: black;">成为了</span>一笔价值4800万美元（约合人民币3.48亿元）的票据融资；② 融资由RTW Investments领衔的<span style="color: black;">公司</span>投资者完成；③ 资金将用于<span style="color: black;">帮忙</span>Allurion<span style="color: black;">机构</span>偿还债务，以及推进其AUDACITY临床<span style="color: black;">科研</span>；④ Allurion<span style="color: black;">机构</span><span style="color: black;">研发</span>了一种<span style="color: black;">没</span>需手术、内窥镜或<span style="color: black;">麻木</span>的可吞咽胃球囊用于<span style="color: black;">瘦身</span>，胃球囊在吞咽4个月后可自动排出体外；⑤ <span style="color: black;">日前</span>，临床<span style="color: black;">科研</span>已证实了该<span style="color: black;">制品</span>的<span style="color: black;">瘦身</span>功效。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Allurion closes $48 million financing</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-17 , Mass Device</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">礼来携手再生元<span style="color: black;">起步</span>替尔泊肽+Mibavademab<span style="color: black;">瘦身</span>2期临床<span style="color: black;">科研</span></strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 4月18日，礼来与再生元<span style="color: black;">起步</span>了替尔泊肽联合LEPR抗体Mibavademab治疗<span style="color: black;">肥壮</span>的2期临床<span style="color: black;">实验</span>；② 该<span style="color: black;">实验</span>计划招募360例<span style="color: black;">肥壮</span><span style="color: black;">病人</span>，旨在探索LEPR抗体<span style="color: black;">是不是</span>能<span style="color: black;">加强</span>替尔泊肽的<span style="color: black;">减肥</span>效果；③ 1期临床<span style="color: black;">表示</span>，Mibavademab对瘦素水平低的<span style="color: black;">肥壮</span><span style="color: black;">病人</span>有<span style="color: black;">明显</span><span style="color: black;">减肥</span>效果，对瘦素水平高的人群<span style="color: black;">无</span><span style="color: black;">减肥</span>效果；④ <span style="color: black;">减肥</span>市场的<span style="color: black;">火热</span><span style="color: black;">诱发</span>众多<span style="color: black;">机构</span>投身该<span style="color: black;">行业</span>，再生元结合基因<span style="color: black;">药品</span>中心<span style="color: black;">发掘</span>了<span style="color: black;">海量</span>潜在新靶点，<span style="color: black;">包含</span>GPR75和INHBE等。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">礼来携手再生元：替尔泊肽+LEPR抗体<span style="color: black;">起步</span><span style="color: black;">瘦身</span>二期临床</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-19 , 医药笔记</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">特瑞药业司美格鲁肽注射液<span style="color: black;">瘦身</span>适应证<span style="color: black;">获准</span>临床</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 4月19日，苏州特瑞药业宣布，旗下司美格鲁肽注射液用于体重管理适应证<span style="color: black;">获准</span>临床；② 特瑞药业<span style="color: black;">作为</span>该药2.2类全国第三家<span style="color: black;">获准</span>单位，成功跻身第一梯队；③ 此前，石药集团和华润双鹤司美格鲁肽注射液体重管理适应证<span style="color: black;">得到</span>了临床<span style="color: black;">准许</span>；④ 特瑞药业积极致力于<span style="color: black;">守护</span>公众健康，<span style="color: black;">加强</span><span style="color: black;">药物</span>可及性，<span style="color: black;">将来</span>将<span style="color: black;">奋斗</span><span style="color: black;">开发</span>和生产高质量仿制<span style="color: black;">药物</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">减肥</span>适应症<span style="color: black;">第1</span>梯队！特瑞药业司美格鲁肽注射液体重<span style="color: black;">掌控</span>适应症<span style="color: black;">获准</span>临床</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-19 , 特瑞药业</p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><strong style="color: blue;">NRx<span style="color: black;">颁布</span>NRX-101临床前积极数据</strong></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">① 5月17日，NRx Pharmaceuticals<span style="color: black;">机构</span>对外<span style="color: black;">暗示</span>，其抗生素<span style="color: black;">制品</span>NRX-101在啮齿动物模型中对肠道和阴道菌群<span style="color: black;">没</span><span style="color: black;">显著</span>损害，与标准抗生素相比有潜在<span style="color: black;">优良</span>；② 标准抗生素<span style="color: black;">制品</span>如环丙沙星容易<span style="color: black;">导致</span><span style="color: black;">繁杂</span>尿路感染以及伪膜性肠炎；③ NRX-101的<span style="color: black;">重点</span><span style="color: black;">成份</span>为D-环丝氨酸并在小肠完成吸收，未代谢<span style="color: black;">成份</span><span style="color: black;">经过</span>尿液排出，可减少艰难梭菌或阴道酵母菌感染的<span style="color: black;">危害</span>；④ <span style="color: black;">日前</span>，NRX-101已被FDA认定为合格传<span style="color: black;">患病</span><span style="color: black;">制品</span>，在<span style="color: black;">繁杂</span>尿路感染及肾盂肾炎上<span style="color: black;">得到</span>了快速通道资格认定。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">原文信息 ▼</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2024-04-17 , PR Newswire</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">感谢本期日报的审核者：mildbreeze，Johnson，章台柳，九卿臣，aluba，RZN，Richard<a style="color: black;"><span style="color: black;">返回<span style="color: black;">外链论坛：http://www.fok120.com/</span>，查看<span style="color: black;">更加多</span></span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">责任编辑：网友投稿</span></p>
论坛外链网http://www.fok120.com/ seo常来的论坛，希望我的网站快点收录。
页:
[1]